# A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct03671018/  
OnCo record `nct03671018` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Mosunetuzumab, Polatuzumab vedotin, Tocilizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT03671018 by Hoffmann-La Roche, with 422 participants planned, started 2018-09-25 and due to reach its primary completion in 2024-01-30. Interventions recorded: Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03671018
- Phase: 1/2
- Setting: An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
- Sponsor: Hoffmann-La Roche
- Enrolled: 422

## Sources

- ClinicalTrials.gov NCT03671018: https://clinicaltrials.gov/study/NCT03671018

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Polatuzumab vedotin](https://onco.cc/drugs/polatuzumab-vedotin/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct03671018.json